MCID: PRS038
MIFTS: 65

Personality Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 15
Personality Disorders 54 42 15 71
Character Disorder 12
Personality 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 34 301.8
ICD10 32 F60 F60.9
UMLS 71 C0029707 C0031212

Summaries for Personality Disorder

MedlinePlus : 42 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to obsessive-compulsive personality disorder and schizotypal personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Norepinephrine and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 74 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3562)
# Related Disease Score Top Affiliating Genes
1 obsessive-compulsive personality disorder 34.9 SLC6A4 HTR2A DRD3 COMT
2 schizotypal personality disorder 34.8 DRD4 DRD2 COMT
3 avoidant personality disorder 34.7 TPH1 SLC6A4 SLC6A3 MAOA HTR1B DRD4
4 antisocial personality disorder 34.0 SLC6A4 SLC6A3 PRL MAOA HTR2A HTR1B
5 intermittent explosive disorder 33.2 SLC6A4 MAOA HTR2C HTR2A HTR1A DRD2
6 cyclothymic disorder 33.0 HTR2A DRD4 DRD2 COMT
7 borderline personality disorder 32.8 TPH2 TPH1 SLC6A4 SLC6A3 PRL NR3C1
8 pyromania 32.6 MAOA HTR1B DRD2
9 pedophilia 32.6 PRL MAOA
10 agnosia 32.6 HTR1A CRH BDNF
11 spinocerebellar degeneration 32.3 PRL CRH
12 dementia, lewy body 32.2 SLC6A3 COMT BDNF
13 kleine-levin hibernation syndrome 32.2 TPH1 SLC6A3 COMT
14 lipoid congenital adrenal hyperplasia 32.1 PRL NR3C1 CRH
15 dyslexia 32.1 SLC6A3 DRD4 DRD3 DRD2
16 conduct disorder 32.1 TPH1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
17 hypoactive sexual desire disorder 32.1 PRL HTR2C HTR2A HTR1A
18 phobic disorder 31.9 SLC6A4 MAOA HTR2A HTR1A DRD2 CRH
19 barbiturate dependence 31.7 TPH1 SLC6A4
20 hypertryptophanemia 31.7 TPH2 TPH1 SLC6A4
21 narcolepsy 31.6 TPH1 SLC6A4 SLC6A3 MAOA HTR2A HTR1B
22 inhibited male orgasm 31.5 SLC6A4 SLC6A3 HTR2C HTR1A
23 impulse control disorder 31.5 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD4
24 voyeurism 31.4 MAOA AVPR1A
25 trichotillomania 31.4 PRL DRD4 DRD3 DRD2
26 hypertension, essential 31.3 PRL NR3C1 HTR2A DRD4 DRD3 DRD2
27 depression 31.2 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
28 parkinson disease, late-onset 31.2 TPH1 SLC6A4 SLC6A3 MAOA HTR2A HTR1A
29 somatization disorder 31.1 SLC6A4 HTR2A CRH
30 dysthymic disorder 31.1 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
31 social phobia 31.1 SLC6A4 PRL MAOA HTR1A DRD2 COMT
32 dissociative disorder 31.0 SLC6A4 HTR2A BDNF
33 acute stress disorder 31.0 SLC6A4 NR3C1 FKBP5 CRH BDNF
34 alexithymia 31.0 SLC6A4 HTR1A DRD2 COMT ANKK1
35 amnestic disorder 30.9 HTR1A DRD2 BDNF
36 neurotic disorder 30.9 SLC6A4 MAOA HTR2A HTR1A BDNF
37 agoraphobia 30.8 SLC6A4 MAOA HTR2A HTR1A CRH COMT
38 traumatic brain injury 30.7 DRD2 COMT BDNF
39 brain injury 30.7 DRD2 COMT BDNF
40 hypochondriasis 30.7 SLC6A4 HTR2C HTR2A HTR1A BDNF
41 body dysmorphic disorder 30.7 SLC6A4 MAOA HTR2A
42 somatoform disorder 30.6 TPH1 SLC6A4 CRH COMT BDNF
43 adjustment disorder 30.6 SLC6A4 HTR2A HTR1A BDNF
44 eating disorder 30.5 SLC6A4 SLC6A3 HTR2C HTR2A DRD3 DRD2
45 separation anxiety disorder 30.5 SLC6A4 SLC6A3 DRD4
46 irritable bowel syndrome 30.5 TPH1 SLC6A4 HTR2A HTR1A CRH COMT
47 retrograde amnesia 30.5 SLC6A4 HTR1A BDNF
48 drug dependence 30.4 SLC6A4 SLC6A3 DRD3 DRD2 CRH BDNF
49 polysubstance abuse 30.4 DRD3 DRD2 COMT
50 galactorrhea 30.4 PRL DRD2

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.6 MAOA NR3C1
2 Decreased viability GR00173-A 9.6 ANKK1
3 Decreased viability GR00221-A-2 9.6 ANKK1
4 Decreased viability GR00221-A-4 9.6 ANKK1
5 Decreased viability GR00240-S-1 9.6 COMT
6 Decreased viability GR00249-S 9.6 COMT SLC6A4 TPH1
7 Decreased viability GR00381-A-1 9.6 AVPR1A HTR1A SLC6A4
8 Decreased viability GR00381-A-3 9.6 HTR1A SLC6A4
9 Decreased viability GR00386-A-1 9.6 COMT FKBP5 TPH2
10 Decreased viability GR00402-S-2 9.6 HTR1A TPH2

MGI Mouse Phenotypes related to Personality Disorder:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 AVPR1A BDNF COMT CRH DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.36 AVPR1A BDNF COMT CRH DRD2 DRD3
3 endocrine/exocrine gland MP:0005379 10.23 AVPR1A BDNF COMT CRH DRD2 HTR1B
4 cardiovascular system MP:0005385 10.22 AVPR1A COMT DRD2 DRD3 HTR1A HTR1B
5 nervous system MP:0003631 10.2 AVPR1A BDNF COMT CRH DRD2 DRD3
6 adipose tissue MP:0005375 10.11 CRH DRD2 DRD3 HTR1B HTR2C NR3C1
7 integument MP:0010771 10.1 BDNF CRH DRD2 HTR2C NR3C1 PRL
8 muscle MP:0005369 10.02 AVPR1A DRD2 HTR1B HTR2A HTR2C NR3C1
9 normal MP:0002873 9.81 AVPR1A BDNF CRH DRD2 FKBP5 NR3C1
10 no phenotypic analysis MP:0003012 9.8 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 respiratory system MP:0005388 9.5 BDNF COMT CRH DRD2 NR3C1 TPH1
12 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Mirabegron Approved Phase 4 223673-61-8 9865528
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
9
Lithium carbonate Approved Phase 4 554-13-2
10
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
15
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
16
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
17
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
18
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
19
Liraglutide Approved Phase 4 204656-20-2 44147092
20
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
21
Ondansetron Approved Phase 4 99614-02-5 4595
22
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
23
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
24
Lactulose Approved Phase 4 4618-18-2 11333
25
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
26
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
27
Cycloserine Approved Phase 4 68-41-7 401 6234
28
Nicotine Approved Phase 4 54-11-5 942 89594
29
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
30
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
31
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
32
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
33 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
36
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
37
Propranolol Approved, Investigational Phase 4 525-66-6 4946
38
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
39
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
40
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
41
Sertraline Approved Phase 4 79617-96-2 68617
42
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
43
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
44
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
45 Mosapride Investigational Phase 4 112885-41-3
46
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
47
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
49 Adrenergic beta-Agonists Phase 4
50 Solifenacin succinate Phase 4 242478-38-2

Interventional clinical trials:

(show top 50) (show all 1411)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
3 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
4 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
5 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
6 Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial Unknown status NCT02540707 Phase 4 solifenacin;mirabegron
7 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
8 Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
9 Brain Mechanisms For Clinical Placebo in Chronic Pain: A Randomized Clinical Trial of Placebo, Active Treatment, and No Treatment in Chronic Back Pain Unknown status NCT02986334 Phase 4 Naproxen;Omeprazole;Placebo
10 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
11 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
12 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
13 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
14 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
15 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
16 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
17 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
18 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
19 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
20 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
21 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
22 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
23 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
24 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
25 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
26 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
27 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
28 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
29 Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders Completed NCT01864551 Phase 4 Lamotrigine;Olanzapine
30 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Completed NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
31 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
32 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
33 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
34 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
35 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
36 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
37 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
38 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
39 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
40 Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD Completed NCT02473185 Phase 4 Methylphenidate
41 Stress, Anxiety and Type A Personality and Analgesics. Impact on Induction Time and Consumption of Analgesics During Cardiac Surgery Completed NCT02756598 Phase 4 Sufentanil I;Sufentanil II;Propofol I;Propofol II
42 Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor Completed NCT02929485 Phase 4 Tolcapone;Placebo;Bromocriptine
43 Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA) Completed NCT00386841 Phase 4 Escitalopram;Placebo
44 Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam - A Study of Patients Examined at the Dental Biomaterials Adverse Reaction Unit in 1993 to 1999 Completed NCT00346944 Phase 4
45 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4 zyban
46 Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls Completed NCT01109147 Phase 4
47 Depression: The Search for Treatment-Relevant Phenotypes Completed NCT00073697 Phase 4 Escitalopram
48 Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women Completed NCT01407445 Phase 4 Placebo;Tribulus terrestris
49 A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome Completed NCT00663897 Phase 4 lansoprazole;mosapride
50 Effect of Intraoperative Dexmedetomidine Infusion on Early Postoperative Cognitive Dysfunction (POCD) in Geriatric Patients Undergoing Hip Surgery Under Spinal Anaesthesia Completed NCT03793751 Phase 4 Dexmedetomidine Injection

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

40
Brain, Testes, Heart, Cortex, Breast, Amygdala, Eye

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 19607)
# Title Authors PMID Year
1
Narcissistic personality disorder: Challenges and therapeutic alliance in primary care. 42 61
32332228 2020
2
Impulsive and premeditated aggression in male offenders with antisocial personality disorder. 61 42
32142531 2020
3
Associations between life-course-persistent antisocial behaviour and brain structure in a population-representative longitudinal birth cohort. 42
32078822 2020
4
Repeated psychosocial stress causes glutamic acid decarboxylase isoform-67, oxidative-Nox-2 changes and neuroinflammation in mice: Prevention by treatment with a neuroactive flavonoid, morin. 61
32474018 2020
5
Efficacy of intensive short-term dynamic psychotherapy in mood disorders: A critical review. 61
32560931 2020
6
Insomnia in personality disorders and substance use disorders. 61
31778972 2020
7
Suicide mortality after discharge from inpatient care for bipolar disorder: A 14-year Swedish national registry study. 61
32450359 2020
8
Psychiatric comorbidity in compulsive sexual behavior disorder (CSBD). 61
32244085 2020
9
Enhanced memory for negative social information in borderline personality disorder. 61
32437207 2020
10
Depression symptoms' impact on personality disorder treatment: Depression symptoms amplifying the interpersonal benefits of negative-affect expression. 61
32553373 2020
11
Disrupted physiological coregulation during a conflict predicts short-term discord and long-term relationship dysfunction in couples with personality pathology. 61
32437206 2020
12
Development of a Short Form for the DSM-5 Levels of Personality Functioning Questionnaire. 61
31107606 2020
13
Perceptions of Restrictiveness in Forensic Mental Health: Do Demographic, Clinical, and Legal Characteristics Matter? 61
31976788 2020
14
Validity, reliability, acceptability, and utility of the Social Inclusion Questionnaire User Experience (SInQUE): a clinical tool to facilitate social inclusion amongst people with severe mental health problems. 61
32016512 2020
15
Positive schemas in schema therapy with older adults: clinical implications and research suggestions. 61
32153260 2020
16
Goal-focused positive psychotherapy in action: A case study. 61
31926022 2020
17
Screening for alcohol use disorder among individuals with comorbid psychiatric disorders: Diagnostic accuracy in a sample of young Swiss men. 61
32135396 2020
18
Risk of Delayed Discharge and Reoperation of Gastric Bypass Patients with Psychiatric Comorbidity-a Nationwide Cohort Study. 61
32152840 2020
19
The Intersection between Criminal Accusations, Victimization, and Mental Disorders: A Canadian Population-Based Study. 61
32363932 2020
20
Antipsychotic Overdosing and Polypharmacy in Schizophrenic Delinquents Explored. 61
31884869 2020
21
ADHD in Childhood and/or Adulthood as a Risk Factor for Domestic Violence or Intimate Partner Violence: A Systematic Review. 61
25995243 2020
22
Latent classes of lifetime drug use disorder in national epidemiological survey on alcohol and related conditions - III. 61
32199206 2020
23
Unified and disease specific alterations to brain structure in patients across six categories of mental disorders who experience own-thought auditory verbal hallucinations: A pilot study. 61
32298780 2020
24
Nonpharmacological treatment for individuals with intellectual disability and "personality disorder". 61
30182462 2020
25
Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis. 61
32348803 2020
26
Co-occurring opioid and sedative use disorder: Gender differences in use patterns and psychiatric co-morbidities in the United States. 61
32527509 2020
27
Employment in Personality Disorders and the Effectiveness of Individual Placement and Support: Outcomes from a Secondary Data Analysis. 61
31820219 2020
28
Schema modes mediate the effect of emotional abuse in childhood on the differential expression of personality disorders. 61
32278927 2020
29
Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk? 61
32305167 2020
30
The influence of depressive symptoms on the effectiveness of a short-term group form of Schema Cognitive Behavioural Therapy for personality disorders: a naturalistic study. 61
32487119 2020
31
Psychotherapy Patients of Psychiatry Residents: A Descriptive Study. 61
32093484 2020
32
Construct validity of the personality inventory for ICD-11 (PiCD): Evidence from the MMPI-2-RF and CAT-PD-SF. 61
32525344 2020
33
A Hierarchical Integration of Normal and Abnormal Personality Dimensions: Structure and Predictive Validity in a Heterogeneous Sample of Psychiatric Outpatients. 61
31729250 2020
34
The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. 61
32541566 2020
35
Biocognitive Classification of Antisocial Individuals Without Explanatory Reductionism. 61
32502369 2020
36
"Nothing Hurts Less Than Being Dead": Psychological Pain in Case Descriptions of Psychiatric Euthanasia and Assisted Suicide from the Netherlands. 61
32501108 2020
37
Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): I. Psychosis superspectrum. 61
32394571 2020
38
Translation and cultural adaptation of the DSM-5 Personality Inventory - Brief Form (PID-5-BF). 61
32520169 2020
39
Electroconvulsive Therapy in Veterans Health Administration Hospitals: Prevalence, Patterns of Use, and Patient Characteristics. 61
31913928 2020
40
[New insights into diagnostics and therapy of personality disorders-Changes in ICD-11]. 61
32542432 2020
41
Personality Disorders in the ICD-11: Opportunities and Challenges for Advancing the Diagnosis of Personality Pathology. 61
32519211 2020
42
The Alternative Model of Personality Disorders (AMPD) from the Perspective of the Five-Factor Model. 61
32526758 2020
43
Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies. 61
32504127 2020
44
Emergency psychiatric management of borderline personality disorder: Towards an articulation of modalities for personalised integrative care. 61
32571544 2020
45
Intact Classical Fear Conditioning to Interpersonally Threatening Stimuli in Borderline Personality Disorder. 61
32535608 2020
46
Consider others better than yourself: Social decision-making and partner preference in Borderline Personality Disorder. 61
30458960 2020
47
A hierarchical analysis of the latent trait of borderline personality disorder and its possible clinical implications. 61
32360894 2020
48
Exploring nonverbal synchrony in borderline personality disorder: A double-blind placebo-controlled study using oxytocin. 61
31774581 2020
49
Metacognitive improvement and symptom change in a 3-month treatment for borderline personality disorder. 61
30712326 2020
50
The Relationship Among Shame, Nonsuicidal Self-Injury, and Suicidal Behaviors in Borderline Personality Disorder. 61
30654709 2020

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 PRL NR3C1 HTR2C HTR2A HTR1B HTR1A
2
Show member pathways
12.66 SLC6A3 MAOA DRD4 DRD3 DRD2 COMT
4 12.17 HTR1B HTR1A DRD2 BDNF
5 12.07 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2A
6
Show member pathways
11.91 HTR2C HTR2A HTR1B HTR1A DRD4 DRD3
7
Show member pathways
11.9 SLC6A3 MAOA DRD2 BDNF
8 11.82 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
9 11.78 HTR2A DRD4 DRD3
10
Show member pathways
11.77 DRD4 DRD3 DRD2
11
Show member pathways
11.72 TPH2 TPH1 MAOA
12 11.69 HTR2C HTR2A DRD2
13
Show member pathways
11.66 TPH2 TPH1 MAOA
14 11.64 PRL NR3C1 FKBP5
15
Show member pathways
11.41 TPH2 SLC6A4 SLC6A3 MAOA
16
Show member pathways
11.13 SLC6A4 SLC6A3 MAOA COMT
17
Show member pathways
11.01 TPH1 MAOA COMT
18 11.01 PRL HTR2C DRD2 ANKK1
19 11 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
20
Show member pathways
10.81 MAOA COMT
21 10.73 MAOA COMT
22
Show member pathways
10.68 TPH2 SLC6A4 SLC6A3 MAOA HTR1B HTR1A

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.95 SLC6A4 HTR2C HTR2A HTR1A DRD3 DRD2
2 integral component of plasma membrane GO:0005887 9.85 SLC6A4 SLC6A3 HTR2C HTR2A HTR1B HTR1A
3 axon GO:0030424 9.83 SLC6A3 HTR2A DRD2 COMT BDNF
4 endocytic vesicle GO:0030139 9.63 DRD3 DRD2 AVPR1A
5 integral component of postsynaptic membrane GO:0099055 9.56 SLC6A4 SLC6A3 HTR2A DRD2
6 dendrite GO:0030425 9.56 HTR2C HTR2A HTR1B HTR1A DRD4 DRD2
7 dopaminergic synapse GO:0098691 9.5 SLC6A3 DRD3 DRD2
8 serotonergic synapse GO:0099154 9.37 SLC6A4 HTR1B
9 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 SLC6A3 HTR2A HTR1B DRD2

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.26 HTR2C HTR2A HTR1B HTR1A DRD4 DRD3
2 signal transduction GO:0007165 10.26 PRL NR3C1 HTR2C HTR2A HTR1B HTR1A
3 positive regulation of cell proliferation GO:0008284 10.17 PRL HTR2A HTR1A DRD3 CRH AVPR1A
4 chemical synaptic transmission GO:0007268 10.03 HTR2C HTR2A HTR1B HTR1A DRD4 CRH
5 cellular calcium ion homeostasis GO:0006874 9.97 HTR2C HTR2A DRD4 DRD3
6 locomotory behavior GO:0007626 9.95 SLC6A3 HTR2C DRD3 DRD2
7 circadian rhythm GO:0007623 9.95 TPH2 TPH1 SLC6A4 BDNF
8 response to ethanol GO:0045471 9.95 SLC6A3 HTR1B DRD3 DRD2 CRH
9 response to toxic substance GO:0009636 9.93 SLC6A4 DRD3 DRD2
10 female pregnancy GO:0007565 9.92 PRL CRH COMT
11 memory GO:0007613 9.92 SLC6A4 HTR2A BDNF
12 negative regulation of cell death GO:0060548 9.91 DRD2 CRH BDNF
13 learning or memory GO:0007611 9.9 DRD3 CRH BDNF
14 response to estrogen GO:0043627 9.9 TPH2 CRH COMT
15 social behavior GO:0035176 9.9 SLC6A4 DRD4 DRD3 AVPR1A
16 regulation of synaptic vesicle exocytosis GO:2000300 9.89 HTR2A HTR1B DRD2
17 positive regulation of fat cell differentiation GO:0045600 9.89 TPH1 HTR2C HTR2A
18 release of sequestered calcium ion into cytosol GO:0051209 9.89 HTR2C HTR2A DRD2
19 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.87 HTR2C DRD3 DRD2
20 response to amphetamine GO:0001975 9.86 DRD4 DRD3 DRD2
21 activation of phospholipase C activity GO:0007202 9.85 HTR2A BDNF AVPR1A
22 feeding behavior GO:0007631 9.84 HTR2C HTR1B DRD2 BDNF
23 negative regulation of protein secretion GO:0050709 9.83 DRD4 DRD3 DRD2
24 arachidonic acid secretion GO:0050482 9.83 DRD4 DRD3 DRD2
25 regulation of dopamine secretion GO:0014059 9.83 HTR2A HTR1B DRD3 DRD2
26 dopamine receptor signaling pathway GO:0007212 9.82 DRD4 DRD3 DRD2
27 vasoconstriction GO:0042310 9.81 SLC6A4 HTR1B HTR1A
28 negative regulation of voltage-gated calcium channel activity GO:1901386 9.81 DRD4 DRD3 DRD2
29 behavioral fear response GO:0001662 9.81 HTR2C HTR1A DRD4 BDNF
30 prepulse inhibition GO:0060134 9.8 SLC6A3 DRD3 DRD2
31 behavioral response to ethanol GO:0048149 9.8 DRD4 DRD3 DRD2
32 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.8 HTR2A HTR1B HTR1A DRD4
33 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.8 HTR2C HTR2A HTR1B HTR1A DRD4
34 positive regulation of renal sodium excretion GO:0035815 9.79 DRD3 DRD2 AVPR1A
35 G protein-coupled receptor internalization GO:0002031 9.79 HTR1B DRD3 DRD2
36 regulation of dopamine metabolic process GO:0042053 9.77 SLC6A3 HTR1A DRD4
37 negative regulation of cytosolic calcium ion concentration GO:0051481 9.76 DRD3 DRD2
38 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.76 DRD4 DRD3 DRD2
39 response to corticosterone GO:0051412 9.75 CRH AVPR1A
40 bone remodeling GO:0046849 9.75 TPH1 HTR1B
41 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.75 DRD3 DRD2
42 neurotransmitter biosynthetic process GO:0042136 9.75 SLC6A4 SLC6A3
43 grooming behavior GO:0007625 9.75 DRD2 AVPR1A
44 dopamine catabolic process GO:0042420 9.75 SLC6A3 MAOA COMT
45 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.74 DRD4 DRD3
46 catecholamine metabolic process GO:0006584 9.74 MAOA COMT
47 inhibitory postsynaptic potential GO:0060080 9.74 DRD4 BDNF
48 regulation of potassium ion transport GO:0043266 9.74 DRD3 DRD2
49 regulation of behavior GO:0050795 9.74 HTR1B HTR1A
50 neurotransmitter catabolic process GO:0042135 9.74 MAOA COMT

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.48 SLC6A4 SLC6A3 PRL NR3C1 MAOA HTR2C
2 G protein-coupled receptor activity GO:0004930 10.03 HTR2C HTR2A HTR1B HTR1A DRD4 DRD3
3 neurotransmitter receptor activity GO:0030594 9.72 HTR2C HTR2A HTR1B HTR1A DRD4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.58 DRD4 DRD3 DRD2
5 dopamine binding GO:0035240 9.56 SLC6A3 DRD4 DRD3 DRD2
6 G protein-coupled serotonin receptor activity GO:0004993 9.55 HTR2C HTR2A HTR1B HTR1A DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 9.54 DRD4 DRD3 DRD2
8 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A4 SLC6A3
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.49 TPH2 TPH1
10 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.48 HTR2C HTR2A
11 tryptophan 5-monooxygenase activity GO:0004510 9.46 TPH2 TPH1
12 serotonin binding GO:0051378 9.35 SLC6A4 HTR2C HTR2A HTR1B HTR1A
13 drug binding GO:0008144 9.17 SLC6A3 HTR2C HTR2A HTR1B DRD4 DRD3

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....